In both hepatocellular carcinoma and ovarian cancer, treatment with cisplatin leads to ADAM17-dependent release of cleaved growth factors and subsequent activation of the EGFR/PI3K/AKT pathway. This evidence concerns the gene EGFR and ovarian cancer.